Relationship between ABO Blood group and Chronic Myeloid Leukemia with the Role of the Oxidative Stress as Risk Factor
DOI:
https://doi.org/10.61841/x7n6qh86Keywords:
ABO, CML, Oxidative stress.Abstract
Chronic myeloid leukemia characterized by the expansion of a clone of hematopoietic cells that carries the Philadelphia chromosome (Ph). The Ph chromosome results from a reciprocal translocation between the long arms of chromosomes 9 and 22, t (9;22). The aim of study are to find if there is an association between blood groups and chronic myeloid leukemia and to study some of the causes that may be lead to this association .Also , it aim to determine the role of the oxidative stress as risk factor. Ninety persons include in the study (45 as patient and 45 as control group). Where the patient suffering from CML, the control are free from this disease. There are ranged from (21-60) years old where they are divided in to four group according to blood group (A, B, AB, and O). This study is based in case control study done in the middle Euphrates center for cancer in Al-Najaf city from December 2018 to April 2019. The sera were collected from the 90 persons and analyzed by using enzyme linked immunosorbent assay (ELISA) for MDA and GSH. The results of the study show that blood group O (44%) predominates in CML patients group followed by blood group A (22%), B (18 %) and AB (16%). The mean serum level MDA value shows highly significance at (P˂0.001) change in the patients group in comparison with control. Also show that the level of MDA in male (900. 99 ± 603.89) is significantly higher than in female (582.28 ± 562.29). The mean serum level of GSH show that significant decrease at (P˂0.05) in patients group (40. 12 ± 27.33) than in control groups (55.20 ± 28.79). As a conclusion from this study, the importance of MDA and GSH in CML patients can be used to detect the complications related to the among these patients.
Downloads
References
1. Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., ... & Ortmann, C. E. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917-927..
2. Shu, Y., Yang, W., Zhang, X., & Xu, X. (2018). Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report. Medicine, 97(42), e12875. doi:10.1097/MD.0000000000012875
3. Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010). Chronic myeloid leukemia: mechanisms of blastic transformation. The Journal of clinical investigation, 120(7), 2254–2264. doi:10.1172/JCI41246
4. Rajeshwari, U., Shobha, I., Raghunatha, R., & Andallu, B. (2013). Oxidative stress and antioxidant status in acute and chronic myeloid leukemia patients. Open Journal of Blood Diseases, 2013.
5. Mohamad S Jaff. (2010). ABO blood group distribution in Kurds. 2010; 1: 143–146.
6. Waseem, A. G., Iqbal, M., Khan, O. A., & Tahir, M. (2012). Association of diabetes mellitus with ABO and Rh blood groups. Ann Pak Inst Med Sci, 8(2), 134-6.
7. Shahzad, H., Asad, M. J., Masood, T., Noor-ul-Amin, M., Raja, A. M., Ijaz, S., & Mahmood, R. T (2013). DISTRIBUTION OF ABO BLOOD GROUPS AND Rh BLOOD FACTOR IN CHRONIC MYELOID LEUKEMIA PATIENTS.
8. Abdullahi A.A., Oorbani M., and Salehi A. (2009). ABO blood groups Distribution and Cardiovascular Major Risk Factors in Healthy Population. Iranian J. Publ. Health. ; 38 (3): 123-126.
9. Sakić, M. (2012). Distribution of ABO blood group in children with acute leukemias. Journal of Health Sciences, 2(3), 220-223.
10. RIZWAN AHMAD1, ANIL KUMAR TRIPATHI2, PAYAL TRIPATHI., et al.(2008), Malondialdehyde and
Protein Carbonyl as Biomarkers for Oxidative Stress and Disease Progression in Patients with Chronic Myeloid vol. 22 no. 4 525-528.
11. Pujari, K. N. Jadkar, S. P. Patil, Aruna Kulkarni, C. G., Tuljapurkar ,V. B. (2018). Variations in serum malondialdehyde levels in patients with leukemia. International Journal of Clinical Biochemistry and Research, April-June, 2018;5 (2):254-256.
12. Giftson, J. S., Jayanthi, S., & Nalini, N. (2010). Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1, 2-dimethyl hydrazine induced rat colon carcinogenesis. Investigational new drugs, 28(3), 251-259.
13. Salim S. (2017). Oxidative Stress and the Central Nervous System. The Journal of pharmacology and experimental therapeutics, 360(1), 201–205. doi:10.1124/jpet.116.237503
14. Mitra, R., Mishra, N., & Rath, G. P. (2014). Blood groups systems. Indian journal of anaesthesia, 58(5), 524–
528. doi:10.4103/0019-5049.144645
15. Rummel, S. K., & Ellsworth, R. E. (2016). The role of the histoblood ABO group in cancer. Future science OA, 2(2).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
